Login or Register to unlock everything MedSchool has to offer!
Monoclonal Antibodies
 
 
 

Monoclonal Antibody Naming Conventions

 
 

Overview

  • Monoclonal antibodies are named based on standard nomenclature that describes the target and species of origin of the antibody.
    • Nomenclature

      Monoclonal antibodies are named based on a combination of the following:
    • Prefix - random
    • Substem A - based on the target
    • Substem B - based on the species of origin of the antibody
    • Stem - mab

Substem A (Target)

  • -b(a)-: bacterial (e.g. raxibacumab)
  • -c(i)-: cardiovascular (e.g. abciximab)
  • -f(u): fungal (e.g. efungumab)
  • -k(i)-: interleukin (e.g. ustekinumab)
  • -l(i)-: immunomodulating (e.g. adalimumab)
  • -n(e)-: neurological (e.g. solanezumab)
  • -s(o)-: bone (e.g. denosumab)
  • -tox(a)-: toxin (e.g. obiltoxaximab)
  • -t(u)-: tumour (e.g. alemtuzumab)
  • -v(i)-: viral (e.g. palivizumab)

Substem B (Origin)

  • -e-: hamster
  • -i-: primate
  • -o-: mouse
  • -u-: human
  • -xi-: chimaeric
  • -xizu-: chimaeric / humanized hybrid
  • -zu-: humanized

Examples

  • Abciximab (ab-ci-xi-mab) - chimaeric monoclonal antibody with a cardiovascular target
  • Adalimumab (ada-lim-u-mab) - human monoclonal antibody with an immunomodulating target
  • Basiliximab (basi-li-xi-mab) - chimaeric monoclonal antibody with an immunomodulating target
  • Trastuzumab (tras-tu-zu-mab) - humanized monoclonal antibody with a tumour target
Last updated on January 17th, 2019
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

Read More...

 Bou-Assaly W, Mukherji S. Cetuximab (erbitux). American Journal of Neuroradiology. 2010 Apr 1;31(4):626-7. Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. InSeminars in oncology 2006 Oct 31 (Vol. 33, pp. S1-S7). WB Saunders. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E. Pembrolizumab for the treatment of non–small-cell lung cancer. New England Journal of Medicine. 2015 May 21;372(21):2018-28. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2003 Nov 15;98(10):2095-104. Ibrahim RA, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, Chin KM, Liu HY, Bielefield M, Hoos A. Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. Journal of Clinical Oncology. 2011 May 20;29(15_suppl):8583-. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Scientific reports. 2017 Jul 17;7(1):5532. Maloney DG. Mechanism of action of rituximab. Anti-cancer drugs. 2001 Jun;12:S1-4. Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, Lin T, Eisenbeis CF, Young DC, Byrd JC. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia. 2006 Feb 1;20(2):272-9. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Cs?szi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. New England Journal of Medicine. 2016 Nov 10;375(19):1823-33. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer.Nature reviews. Cancer. 2012;12:278-287. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer biotherapy & radiopharmaceuticals. 2010 Dec 1;25(6):601-13. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L. Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine. 2012 Nov 8;367(19):1783-91.
Feedback